Short answer
Guardant Health, Inc. (GH) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Board expanded to 11 directors with Kevin R. Sayer appointed Class II director through 2029 annual meeting.
Guardant Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded to 11 directors with Kevin R. Sayer appointed Class II director through 2029 annual meeting
- Sayer brings Dexcom leadership experience, including CEO through January 2026 and executive chairman effective January 2026
- Director compensation: $500,000 restricted stock unit award vesting over three years, plus $60,000 annual cash retainer
- Robert A. Parks appointed Chief Accounting Officer and principal accounting officer, strengthening accounting leadership after roles at Fortrea, NetApp and IQVIA
- Parks eligible for annual salary, incentive bonus and restricted stock unit awards under the 2023 inducement plan
Item EX-99.1 · Exhibit EX-99.1
- Kevin Sayer appointed to Guardant Health’s board, adding former Dexcom CEO and current Executive Chairman
- Sayer brings digital health, medical technology, and operational scaling experience from Dexcom and prior healthcare roles
- Appointment supports Guardant’s strategy in liquid biopsy, AI-enabled molecular data, early cancer detection, and personalized treatment
- Board addition may strengthen healthcare-industry credibility and strategic execution as Guardant expands precision oncology offerings
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Guardant Health, Inc. 8-K filings
Get the next GH 8-K as it lands
Follow GH for push alerts, or ask the research agent what this filing means.